DUE TO RELATED PARTY
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
DUE TO RELATED PARTY | |
DUE TO RELATED PARTY | NOTE 3 - DUE TO RELATED PARTY The amount due to a related party is owed to a stockholder, is unsecured, non-interest bearing and has no specific terms of repayment. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DEVELOPMENT STAGE COMPANY The accompanying financial statements have been prepared in accordance with generally accepted accounting principles related to development-stage companies. A development-stage company is one in which planned principal operations have not commenced or if its operations have commenced, and there has been no significant revenues there from. ACCOUNTING BASIS These financial statements are prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America. The Company has adopted a November 30 year end. BASIS OF PRESENTATION The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. CASH AND CASH EQUIVALENTS The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At November 30, 2011 and 2010, respectively, the Company had $1,275 and $1,464 of unrestricted cash to be used for future business operations. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company's financial instruments consist of cash, prepaid expenses, accounts payable, accrued professional fees, and an amount due to a related party. The carrying amount of these financial instruments approximates fair value due to either length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. INCOME TAXES Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. It is the Company's policy to classify interest and penalties on income taxes as interest expense or penalties expense. As of November 30, 2011, there have been no interest or penalties incurred on income taxes. REVENUE RECOGNITION The Company is in the development stage and has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable. CONCENTRATIONS OF CREDIT RISK The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. STOCK-BASED COMPENSATION The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718, COMPENSATION - STOCK COMPENSATION which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered. There has been no stock-based compensation issued to employees. The Company follows ASC Topic 505-50, formerly EITF 96-18, "ACCOUNTING FOR EQUITY INSTRUMENTS THAT ARE ISSUED TO OTHER THAN EMPLOYEES FOR ACQUIRING, OR IN CONJUNCTION WITH SELLING GOODS AND SERVICES," for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. There has been no stock-based compensation issued to non-employees. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. BASIC INCOME (LOSS) PER SHARE Basic income (loss) per share is calculated by dividing the Company's net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no such common stock equivalents outstanding as of November 30, 2011. DIVIDENDS The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown. RECENT ACCOUNTING PRONOUNCEMENTS Orgenesis does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flows. |
BALANCE SHEETS (USD $)
|
Nov. 30, 2011
|
Nov. 30, 2010
|
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 1,275 | $ 1,464 |
Prepaid expenses | 1,065 | 153 |
Total Current Assets | 2,340 | 1,617 |
Total Assets | 2,340 | 1,617 |
Current liabilities | ||
Accounts payable | 44,513 | 6,838 |
Accrued professional fees | 5,000 | 4,600 |
Due to related party | 35,500 | 500 |
Total Liabilities | 85,013 | 11,938 |
Stockholders' Deficit | ||
Common stock, par value $0.0001, 1,750,000,00 80,500,000 shares issued and outstanding in 2011 and 2010 | 8,050 | 2,300 |
Additional paid-in capital | 46,950 | 52,700 |
Deficit accumulated during the development stage | (137,673) | (65,321) |
Total Stockholders' Deficit | (82,673) | (10,321) |
Total Liabilities and Stockholders' Deficit | $ 2,340 | $ 1,617 |
"+ text.join( "
\n" ) +"
" + text[p] + "
\n"; } } }else{ formatted = '' + raw + '
'; } html = ''+ "\n"+''+ "\n"+''+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+' | '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
NATURE OF OPERATIONS
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
NATURE OF OPERATIONS | |
NATURE OF OPERATIONS | NOTE 1 - NATURE OF OPERATIONS Orgenesis Inc. (formerly Business Outsourcing Services, Inc.) ("the Company"), incorporated in the state of Nevada on June 5, 2008, and intends to develop to the clinical stage a new technology for regeneration of functional insulin-producing cells, thus enabling normal glucose regulated insulin secretion, via cell therapy. Effective August 31, 2011, we have changed our name from "Business Outsourcing Services, Inc." to "Orgenesis Inc.", by way of a merger with our wholly-owned subsidiary Orgenesis Inc., which was formed solely for the change of name. |
BALANCE SHEETS PARENTHETICALS (USD $)
|
Nov. 30, 2011
|
Nov. 30, 2010
|
---|---|---|
Common Stock, par or stated value | $ 0.0001 | $ 0.0001 |
Common Stock, shares authorized | 1,750,000,000 | 1,750,000,000 |
Common Stock, shares issued | 80,500,000 | 80,500,000 |
Common Stock, shares outstanding | 80,500,000 | 80,500,000 |
Document and Entity Information (USD $)
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
Document and Entity Information | |
Entity Registrant Name | Orgenesis Inc. |
Document Type | 10-K |
Document Period End Date | Nov. 30, 2011 |
Amendment Flag | false |
Entity Central Index Key | 0001460602 |
Current Fiscal Year End Date | --11-30 |
Entity Common Stock, Shares Outstanding | 80,500,000 |
Entity Filer Category | Smaller Reporting Company |
Entity Current Reporting Status | Yes |
Entity Voluntary Filers | No |
Entity Well-known Seasoned Issuer | No |
Document Fiscal Year Focus | 2011 |
Document Fiscal Period Focus | FY |
Entity Public Float | $ 0 |
STATEMENTS OF OPERATIONS (USD $)
|
12 Months Ended | 43 Months Ended | |
---|---|---|---|
Nov. 30, 2011
|
Nov. 30, 2010
|
Nov. 30, 2011
|
|
REVENUES | $ 0 | $ 0 | $ 0 |
OPERATING EXPENSES | |||
Accounting and legal | 67,363 | 15,410 | 106,333 |
Transfer agent and filing fees | 4,219 | 2,488 | 10,997 |
General and administrative expenses | 770 | 3,275 | 4,843 |
Write off website development costs | 0 | 15,000 | 15,000 |
Incorporation costs | 0 | 0 | 500 |
TOTAL OPERATING EXPENSES | 72,352 | 36,173 | 137,673 |
LOSS FROM OPERATIONS BEFORE PROVISION FOR INCOME TAXES | (72,352) | (36,173) | (137,673) |
PROVISION FOR INCOME TAXES | 0 | 0 | 0 |
NET LOSS | $ (72,352) | $ (36,173) | $ (137,673) |
LOSS PER SHARE: BASIC AND DILUTED | $ 0.00 | $ 0.00 | |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: | |||
BASIC AND DILUTED | 80,500,000 | 80,500,000 |
COMMITMENTS AND CONTINGENCIES
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
COMMITMENTS AND CONTINGENCIES | |
COMMITMENTS AND CONTINGENCIES | NOTE 6 - COMMITMENTS AND CONTINGENCIES The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities that become available. They may face a conflict in selecting between the Company and other business interests. The Company has not formulated a policy for the resolution of such conflicts. |
GOING CONCERN
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
GOING CONCERN | |
GOING CONCERN | NOTE 5 - GOING CONCERN The accompanying financial statements have been prepared assuming that the company will continue as a going concern. The Company has no established source of revenue. This raises substantial doubt about the Company's ability to continue as a going concern. Without realization of additional capital, it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty. The Company's activities to date have been supported by equity financing. It has sustained losses in all previous reporting periods with an inception to date loss of $137,673 as of November 30, 2011. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan. |
INCOME TAXES
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
INCOME TAXES | |
INCOME TAXES | NOTE 7 - INCOME TAXES For the years ended November 30, 2011 and 2010, the Company has incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. The cumulative net operating loss carry-forward is $137,673 at November 30, 2011, and will begin to expire in the year 2028. The provision for Federal income tax consists of the following as of November 30, 2011 and 2010: 2011 2010 -------- -------- Federal income tax attributable to: Current operations $ 24,600 $ 12,300 Less: valuation allowance (24,600) (12,300) -------- -------- Net provision for Federal income taxes $ 0 $ 0 ======== ======== The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of November 30, 2011 and 2010: 2011 2010 -------- -------- Deferred tax asset attributable to: Net operating loss carryover $ 46,810 $ 22,210 Less: valuation allowance (46,810) (22,210) -------- -------- Net deferred tax asset $ 0 $ 0 ======== ======== Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $137,673 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years. |
SUBSEQUENT EVENTS
|
12 Months Ended |
---|---|
Nov. 30, 2011
|
|
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | NOTE 8 - SUBSEQUENT EVENTS On February 2, 2012, 33,873,049 of our common shares were cancelled. On February 2, 2012, the Company signed and closed a definitive agreement to license patents and knowhow related to the development of Autologous Insulin Producing cells. As consideration for the licensed information, the Company will pay a royalty of 3.5% of net sales, 16% of all sublicensing fees, an annual fee of $15,000 and milestone payments as follows: * $50,000 on the date of initiation of Phase I clinical trials in human subjects; * $50,000 on the date of initiation of Phase II clinical trials in human subjects; * $150,000 on the date of initiation of Phase III clinical trials in human subjects; * $750,000 on the date of initiation of issuance of an approval for marketing of the first Product by the FDA or any other equivalent authority; * $2,000,000 when worldwide net sales of the Products have reached the amount of $150,000,000 for the first time. On February 2, 2012 the Company completed a private placement whereby we issued 500,000 units for gross proceeds of $500,000. Each unit consists of one common share and two share purchase warrants. Each Warrant is exercisable into one additional common share and shall expire after three years. The holders of such Unit must exercise half of their Warrants, at a price of $1.00 per warrant share, for additional equity of $500,000, upon the earlier of: (i) our company or our Subsidiary signing an agreement with a clinical center, and (ii) 6 months following the closing of such placement of Units, and the other half, at a price of $1.00 per warrant share, for additional equity of $500,000, upon the feasibility of enhancement of cell propagation capability for three years from closing at a price of $1.00 per warrant share. On February 2, 2012, the Company entered into a fee services agreement with Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. whereby upon closing of the private placement, the Company agreed to pay $80,000 and issue 1,390,952 common shares. In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to November 30, 2011 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than those discussed above. |
*BU.0V95AKH)9;\>*3U;2'TC6CR))GO@HINX:( MD/9/NL4^S@W[N7KDIVF&-@5^2W>8:09T M`J2O0P]>/)!)N'`RN:D7]UZZG<8&/D$G>H%L(V^-%;XJML:XPZ_EVZN&M^\0 MV6[4;*%/P)/_%;\>"25N@E2"-!S\I'7T[N 2 C`!_GTG0X3U!["M#RI;S[N@AA^ZW4\9&A0FD9S\8I'GG$('P# M!HX"N"KB/)V@28QGN%MAD%&>[UZW)-^]0VYK')QOYFZ%YQ&R^5:72V"ZVO+B MLK>]3WYCIZ[MXMM)SB['N0K/`>Q0B7ME*_%!%R0/7HFYBY#)3?FW3<==-QT' MD)@V(AX&$T6_GZE5O)8@-\_C;3CFPC@FL_/[NSME]DT;SD>?)Z,ANX])5_I] M[7ZBCR:?I]IXU!^I%;`M6$X="@A".Z8J@WM5UV;J6-'5P529Z=_V%R"=91U< MIU$ :*9,!1<"Z('5231^ &UL550) M``.074Y/D%U.3W5X"P`!!"4.```$.0$``.U=>W/C-I+_>[=JOP,NNW4SKO)# MSF3N,G/)[LJR--'%EG22/)/4UE:*(B$9%YK4\N''7MUW/S1(2I1$$"`!4O!5 MKNJR'AOH;C1^`+L;Z,9W?WE^<-$C#D+B>]^_N3SOO$'8LWV'>*OOWY#0/_OV MV_?8/0 MV1GT<(GWZT?XS\(*,:*\O/#[K^ZC:/WQXN+IZ>G\>1&XYWZPNOBZTWEWD37\ MZ@^__]WO6../SR'9Z?#T+FM^>?'3[ W=Y_APZ.4&7Q-UA0_MC#X /6'W>K @YU, M;*!3LHX9&[93`.&,LF_G:;YQ8>OT@S=Y3;RA),*S;!]CXZ2[WB^?QL/1I]YX MU.M/1]U%&`66'67]F,#?O^$VN\B+`&UWA`APZ,>!C?>HT?_Y1<28Z>"-0`=` M[@U\E2AE^-YA[^QN]N;/C"Y*"7]WL66]+VPWL)$?.#A(OYQYV:W`SGY!?Q2( MD[:XL'VZOZZCLTPRUGT9^`\E*LRX^@+%7%2=[?Q78VF%"R9N')ZM+&O-OF87 MV(W"[#<,%V>=R_3+^,?TU[_,R,HC2V);7M2U;3_V(FI:3'R7V`2' _2?8?>9A+Q%6-I'?>W)B*2TY#(&IRAA@;8\T-^`R]^-@Z",3@Z0)S]/ M[0%N2)W)!SRWGG$XL8@SPONF04E#96CQF:O@*:&*(B"+UI2N:>CA#WL?,B*E MMX>32>`O273CA[Q=*-=`&1>'S%3P,.K/T M2 MIY:Z,N[>-'`:*?D!?*8JT[JEBBS/02[0U6&/J4OL^'8,^SR+;15(/K_'R%JM M`N9)(NL!6"%_B:R"$:$EQN&Y*=`MUTW>Q1%AJ+V=JQN&.`I[<1#0*>'XO^5M ME?>S4A%4UD!*$EF,@2DHD1KV_EXGH?JJF`FQ?;[R'R\<3!*XT!_V44)_]4N? MXI3:8PGK*5[[`>`6S+5X_VLG;%X;*[*"J,`EH8\RU&PXH(2%*?B1544&H6J3 MTJ(S%Z_7+K/X+;=GA?<#UW\:>DL_>&!?!L%>)-M;W<&K)J9:=&4RN>G?]D?S M[@WJ=6<_H,'-^`L:C@;CZ6UW/AR//IH"PIK:.7#ZZLQB>Q"E'@5(10W-1^)@ MY^KE+L3.T!L0S_)L^'C;$7DD$<$\L[\"`66@5A=6R6W`$0)V*..'%B]HPPMM MF9F&V.IJV@=MW4EM-6P18"O$USCYWZ$W7N/`@CV_9ZT)76R"W;4"`1UACHK" M*MF$]_1?.$3$0W[&)C40$[>"6`OBLMDS;K.MKJF"B$FM>:WO4E]U9Q`ZO[X> MWMS-^]<%_O1^"R5GFL-.!3&,)*(T44I4EQNM(*N4#_U(9W:%D1<_+'``'G1X M;U&1*&Q1[!&*=Q*&,=VX`?9^','U"+@X@Z)[B_I,`48QW==@H=B6:\=NLE06 M5DALUL4A;AS1!OW)S"@/G*/6O/M="KDVCS-\^]=[WZ6Z"9.HM\CHY7?0<)`A M$D;M%&-+_5^MM1_^![K&2V*3R!3HR.OA\.1";E;:`];-]B/&05*^A3)T"MBI M8(5='D$YHJ9!I&"\^YC@ZO #VP MP3U:+CN8I6Y0$+Q0J^"SY<;[LR_921E9 SC MK,H$-1QCIOP#RQUZ#G[^$;_P@\M[[71$E8M9ZP@G)Y01(XTH;5-0(QQ\00"Y M3/%'#\MM7-FZ8;DB`DV%Y4J$U1*6NTM]MPV?UQ>2*U&19$A..*''#,E=QWCN M3['+;J1;0>X[+QV4*R'10%A.++#BO23&!T#KQ!A%/@H27FA-F1FS;:KH1QR. MDYW1^@&YZS1TU/6<9%,7G[E)=U,*W5413`5H&1]FTJ4?Z1PK4W!6527Y^%;U MR6K7B:!R[5F=24K._GHH<2FD26AQ,*H*K/H)WVR&;S/*)[`O;CP1]D/?;$^D MJLZ*_))ZL]P>F#<&1O]YC;T0AX(0"[^],DR%HJA@ BQ8W1?WCP/19,GKFO'V3(:W$99U4=_X)`12BJLP^H@Q.-T< M3FUYF`8Q&7T<;&+2,W04H%$3 A?,`[V@R:%L0N!!V4HA9R MPJCZ@RYE@:@+CZ)[C%X`'ZQD`GK7N:`K!CCINI2D;SPR=Y38173Z%?:7B,(O M]%WB)!$_EMH%7^2=D:^9\W>*/,PR@D@NE?$4/=T3^QZ1$%E1%)!%',$6!6%$ MUM."G>H<#9?LGS@)^S@^M3@]/Z+\<`@K<$>(97*ADZ[(,,M-I6R@^S8IJ;J@ M1MV5DIOM?&BIREJJO\3G@>6%2QQT5TD4:T!HE]4`'YSH"!HK+6VQ$$JW7%+J MR%IEP<@E8\!RVG0M9SUC$"WES(5F^`^PC ,D3S_D_S MJYMQ[\>"S:ZXG;9"1`>LM54BTE401HO$I;5?I`LHM2JR:`^^IL8VM4'B`.\E M2Z^A>LM+NC5G*8U/]]@#2X6V!HL)A?$"PE(16#N.'R_H;KWP8]BS4ULIN;1+ MF[([:2]@5]%51&G%U!P""BL?Z+*5%7B,FX4@-N][S`Y++"(0+2+4%'H+Y04# MRW5?:#-FT,+R8[;3PG*A3A\*[S&UGL`4.SE'Z>CP1_36.@%BE'-JL#D$-))D M;\"BI,[V*OG^!"3<&("0XA&&S,V"F_" )94B-)P(-\'*) M;2HKDX8:KH4CH?WL$_1@>?0+"K)G4F&(4%F9Z0QTPTWA'ALGOZ/:XJ@'?K2\ M%_1`_[1*+H WR)/_;W-10T\*'K(9T3JC.;9=. M+!MWI@QH$X!OQ))Z4E.=)3UL+?>PN&ON^BCS%'B#H[#%CP2J$S#-:\;2*5/[ M=BDSU`14GV1-.13/*$O9(!X!(>B2"BP"UW^:D`X]^;'KH`7M_0R3"6Q\^">X M3H1^H[&S7:VPS<`FDX/-QD6RTSN[])]T=/2_L`O0I K/P<6BD,E/9\3!H,95@!.?D$U$U77-_F:%'S>" MYS;C#2T/)^I-QH$L)Z$$=2\VF99OF314?YBE'IPPI/L4R_2?L'DB.FNL-V0H MT`XA([A &-,SJB1 M"%;L4\*'FG,;1M3Z"\LO'1YM2*(P";LY"0X0LW>I!^C;A+D;3R2Z1T]2`S?* M(I767MXZK0C2HR2MRF>K-I*FJG/_SI'571=;4>+20.CK2,&ND$=[C,)Y\,A, MT*-;S,H/^"F-NZTT)#06LM60SLCHHHRP*;`0C/LPD[%$WRW>'@]6ED?^R3Y5 MO .5EV:-.ZR^Y\@-R)R$P`H5 M2BJNKV,F]N_=DN=L&N)^#:3P ;+WWW$8,1L- MZ@:`#JAG,\)1\C8*7-6=^Y*E,435_YM@I>$ .]+] MS)%6&V,VZ\^-V_^*QUG\H-&Q@0"78DAB7H"#R:Z]KI+KC]O[]*)G?BL2T7+5 MJ;K02I_A\>WM<`ZQNV0GZXW9&[C]41,O_38WO-+#SM(QFK;&ZNFHZ$I87>!J M2M^>9+&M+(>T\VU!U%_815\*=XE`6I.XT_R0W33NSK>-I'$KCNFW1.Y7ELA= M,M_<5&[AJFK53]YZ]WP7.-=&AW=[R+*!]6X*9$K'7>"&\G3='BCZ5@!'-F%6 MK^@*WJ&A7ZWKY!4:#DQ$O92!(RF6DALYGLW0I#]%LQ^ZT_Y'5.D]HF.`2E(G M^S"K-%?M`:]RF>8FBS(W6X+Y^A647:Y>9%EG267UPE7)=U:N=%6^K<;B504B MZ"Q?E9`WO8!5@1+X):RX$]'P>QCR%4$E.^EX*:/AJJ#I/=/=\HP))S0VKSAH M-<44/*EA8('06;P(\3]B"O\^RU86!<#X[36\OBP01>GZW=W5K/]?=W#_#JK0 MS+6'LK1(7QJU.AB"*>M"6@6'3T)+@>F8KS2._`C+AX?E^S?PAJ-`5+7+JP?' M612)P_G/VE=1$Z,J7U6\H1FWNJJJ1OQVI10X6Z\/3+^&$ZAC)'%-B=]!5YW@ M$F'4/D>WM]WIS^PN^/#3:#B`-VKGJ-OKC>_8602:C&^&)AY'B/7"J20LG*7Z MQPQ]5H=EO'SW_C*QKM8N* H%?X M$@EO#Q0H_I@6KK0IVX3-J@4L[`WIU_SJN+S%=MQ;5#PS+/FCIEM3^B"1T#-M M^G='67Q7JLW(XQ?LNC]Z_I,W8Q4ML3,,P_B@G).XO89XHT`4#:%&X'#V*[!` M&0^4,#$%)M+:.(PO2LU,?2M[>X5H_P9121*O1" J,8NQ9F"G&KJR-NR M52>IS3KGF[.\%U:%G OT:0[ MU1^1:VA(I3&YHG&9LLH4]')85[XF-%MT%R1?)VS@2<)&3ARODH+C6D/6*G)* M)+*;*7))BKJ$P$=QNV3?<33F;':*DY+6V6VITCJKG,8:/FEE0BA]O1+W''5M M.WZ(DWM(UW'`:G7?8Y0K4T>=>VME'*#*-7.XV8OGI]5*!OX#GEO/:3SJ"GMT M-GCG++S6.JH6E(FA@J[)=/QY.!N.1V@PGJ+AB)KPU*CH_F2.O2ZIA(+Z!.+) M4*^#6KT*:J,U4)NN@`IE\MLK?]I"\=.DA#6K N;^WOI\5M-`3."EAJ")8E5!$C:PH\2L=\&!+CZKG-3RWU=7$8 M0>U^[O 6E."IN"@;+"'7TR>>H]>$&3H/5+!=NH[<#!2 M@4!3!4!*A%7-G]JIC+/ADZN,8QKNJJM(LN*'<$+KFW9992M6T2J(L4-Y+W$8 MLJ=%.`^NBOLHF7?2(JEM8#MERX`-RP'-^&A]A57KB&1NV)!L=&^=M&+9"7*V M;O3V'<`T#9EX>^FP7)4891-*ZS5O%59$;]-I07-*ML`DW/FSEN2?/",M^3Y` MT!0T\`9:E--SJ-(CQ%CD#ZM*N^B+MC1T')4/LN@^AM(E>^FYTZN($E4X8)*' M4XO)W3)%PG27`M-?\.O5I`W(5?$RHU87N^_&+JTXR4%`DHR9',B,\!/[$\]! MDNRLYQ*CM)!*&$LR(0GC!=G:2S]YIM3WT'_&'D;O3Q$4[T!_17\Z[UQ^_1Y, M/!1"+]-06$UIA?<@*TYM>ZBE-J6-L1,.Z(A!$CC\'"]SR9X 1>=MW?-%1*JVY#Z@LGJ/L).%UYC7^%1#.?6X^7! M+0F!25>9C#(`ZPJNA,O^\-,/<&>M^[D_[7[JH]'=[55_RO+\H*3/#(WOYK-Y M=W0]''TRKMIW78WM8UAMKMN#]B?V`+W;]9RN\T`\`M)$Y!&G)^L<)(MZ*0-7 M4BP5G*8LV#/UU@X3A-,,)=/`*:F5?2Q6FJVC/)^=+(MN'-W[`?DGM[Y960^= M3VKSQ%&Z/[]3X25,_!IKP\(TJ$EHH^3)[?+9.6HQBYV->&(%[#4=NC3&U&H/ MMD$B4=Z]#LI-%,"H.SPE[X<5*;W'$;$MU[A-4Z.2),I)J(&@S9=T'!*Q,R"X M$C#T>M::1);+03NOM8;W;$K%4$'EEC2[M7%&/&0GU$U#J$`)AX_$2$Q&FWML M6F3XAGAX2'_D1R&FK8`7G,E:*.&57T-Z"+&.&_FP8;_M@/]ZERS6NJ;OXS MMH)\2>4/!9GSO$+Y;)?U?Q#(U7-E<;S6TWS5U;3G#O; MW(KF@K5T%+>N]!79_68Z'3A];\/F0O>G@%ST"*31GSKGG4[G\A1=GO[[^\XI M_9G^/_JV<_J>_=3)'+STX`IB#/XVZ`,7D$![[/?TAXXI.!2ILL3E.^JKI)RK M3>65JP6==)1/DQ!*R<2M
H+:K@,C@-9.&TU5830")RD. MDQ(TNDB,"")\11_!`YJ7/("\UTB?YS/7];1QSNMA-,UU>.9ECQ>7*?IX1:5% MX41><^TEI?66\'QEY9B%`3VI::CO+N?+78ACS3(]E!QF27%TUV "*X;J0GC`:$/;%+1(#KUX M5Q5,09N9"QAN!Z17XL5M-60HE(B@EI7`"!M[G;%TX(?Y!D+E-UO3YK/O MQG37#UX&Q,5!T7.&Q>TTU+;AL-90WV9#&26D38&(<.R'=6Y*]:YF4J7674F8 MIJB5LE'%8:LK/]F4N18,=]_N*%5S_7EF1R*'%_K2"HV%`17I;DI(J"*8^IE0 MGA%*.*&W*:\3DQ!312UY"%6?,!,K)`GLW!J$6JR8I+4L?7?V`QK )7?QY/<_UR.IH'Y[59J]9\WV*5RSQR8M&UD-1":+"9AJ,]V+&&FSW+6$$ ME$T!C6CDAY9[F<[K&W3)>5%2,F$2D$ ';C,D)RJKTP3W8M>%!*EG5%,0Y*TS:$;-ND]7"NRO`::T_VW97 M#.V9MLE%;-/`)="",,.V:#;:@U*NPCA[G:(/IY[K@`#HF1V;>]8B*5JTWX.# M.@V$E0&J;W!*UZ?2!T*LW`,AN 7W'&<]OF<"O.Q-X.]NRF<#[:ZDI0R>]DC$@ MH6VYJ0P<6X?;5,G<$0F@Y%.FJ7()<034C;1Z1#K(&SYRL]`47+ITY3JP>@>N MM?^DZN'?E8!1R$HI[S8CB("B2?-?.-3\I!>H-2__#?V)_B[[%?W/P@HQ_ `L``00E#@``!#D!``#M75MWVK@6?NZL M-?^!TWG($R$T[9FV:WIF.6!:5@GF@#-MG[H<6Q"=,18CV;G,KS^2#<$WV3(8 M+#'M0Y+"EKSW]VU)6]*6_-OOCTNW=0\P@ VW M;]^\:W?/?O_/SS_]]J]VNS4&J.=:.""M=@L.H`M:LP#Z8%-'Z_+\]>O+UZU6 MN\U*N-#[\SW[<6L1T*+/\LB'EW>^OWK?Z3P\/)P_WF+W'.%%Y]7%Q65G(_CR MYY]>O`B%WS\2F"CP<+D1[W:^7H]F]AU86FWH$=_R['5!`M^3\/,1LBV?&5;^ MR!97@OVOO1%KLX_:W5?MR^[Y(W%BBLZAFW@,+0\\0""!GGUNHR6MK$O_75[$ MRK!:*\*1*;(&I/ONW;M.^&U 1'2R!YV]^:YZC>S[TGX;>'.%ER-W+5FC5>_]I M!3Z\)'"Y T@>1]J9RQLHOPG5WMJ:L,"!4+/Q\1#](/!8\^L!S M@+-Y,+/@(,8R?=8*N H=T2'UNVOZG'M6Z! M^^%,N%BGJHIQYR/`/E^@^XX#8(@0^R-4OWW173>I7^A'WZ/'3\$"LJ=Z_MA: M@I3"7+&X@G%2-9Q4UL+VIDKZ9\CH&=?WUQ*=E85I?6W[#KK.IO0 MC01VI MW:/J8,L=TO'T\3-XXG;K:3G%H.<8FT_!FV-1T`LP,W0`B6VYWX"%^7T.5U0Q M(O@FYW/Q[R,W![1<(F_F(_O/V1TUGAB!S^)L-@/CMXVB0HKQ(P)#/E._'IHY"X3YW5922DDN4H;F@__VR,TD:L53L$+8ISXQHS@&A-]`\L65I(-G M>CXO[X[+RQ_(#2B(.'(:/B%I.269R!C+F:9=')>#+\!U/WOHP9L!BR`/.$-" M`H"Y7/#DE>2$:SR'FZ//H;>!QX!^DM=">)**\<$UF,/$T6?9D6+1]%.,B[BL MTFPDC.;P<;0I=V3#)+AUH3UPD95>B\R740S_'",YN#_/OW_K9(P;T0]J6VZ_ MTD;:N*?//NFZ.=MU73U9R3$7T)-/WL=1YQ:Y#7T@(.V%9:TB;P6N3S:?I-UV M_?%W%GN!Q?UANP.M!2PI)00['N^( :#^PIIY,I`=3AH&490?:!MP7^4+(%$B8)EVH7CDX5ST -E&_8=QP8:3.QH#/T>M8*^DRU_/&>(ZT4*UR3Y1OA MP3UPT8JU?-H%+(#NT0G6"D,"^F`.;>C3F"58!N%`V`\P]!;I$KQ(8/^*E:*\ M#B"EZT*S$`@/;&JQEV>H=.%&V:+,CBN":C%5#D+)>8*CII1,M*D^-C_IYK"G MC>I),$E5V5BZ24H/63JH<;"\!=B81RGS=.X6AD7450S_#N`^)+:+2(!+%V7K MJ+GI-)<=,W*DZ`-VYC$W)V:-A'2Q\8^,I*89B$V@J),9.%3:"9UM`G#H?>43 M1VY)63@JG-4+02`S<5$?H07^'<+P;^"4$Y8IH1I169.EFUIFM`V/(0B3LY96 MDYB-J=+-Z"J C#-<\9@45F M(XPCU#"PI1["\.795Z._YX-J8LLC EBRDJI0)4P`C5.$_,;R!<,?6#,YU_` M+:%_Q;8>>XAD4OI%2JB`OY#E-6[SY6//0F*\0CB$AP=WCI`J".?9=Z`[O6J, M<$0C&R5H*+#R0#=Z[3LC'R%"!M30'F*Q0D!57NN./'(%Y@B#2,ZT'@&YAA[" MX1T#/J`,L!$O64NT970-_#M$O[FG(JR!\S@^I@8J><]1F3G0_67[^B6U:@W5 M%1VTY[!XI2@KK1[?.18?Z'JS?0[A(JH8\RD.'3$!E1B(VW6@N\MV!UVWL$?M M()L]P"N+0)LV\#YT`Y^[CU-62B5Z2A$XU&5GNY/V!<#%'=5-NZ=V+D`RBR*V M[5&RP%.Y&B76?:J#<_")V94V&_:T<;\_'-V8>C]G9I"6:!CI71UL,UO(&%RR M.'3,[;>>-OLT&!E?:ME]VU;6U.;;5@,UMZ]^;/7\@[9ZQL!G=\/0B.@>TC9P M]71#`)TQ/(_7FNW#>Y'3]#M4)`N#A8/7+@#)R/)V?L@G,";3,#>[NV6*N[C9 MTM&B.?\+UC-S=NS51IX-79#0VD3U-,^#/.HDG.0P)!Q\0W.SP&[LL+G`+]/T M-4(';!#IG8D"X*3K**CY&%CL3%OT.V;P^HQC>8:5:`4GT:BK`"9=LFA6^>0= M<<( "CYT:'\-EYE\/D[Q67 ME%&2%D$X%.@E*U^;4ZD*) F,W0W'_@GP?ER\O)J8`[)_:J^7!(%_"*6[QW MPST- MTY:>C'#XKE2%G(Q7[+JK@29=,GB^^N)OQ"DO>\(L"[X\Y]?JE^RO0O^9^1;V M&[UJ_^#N\;W[#W(0:FQ!:O=.+J)[3J,.,@M6*S?,G;%<9OS`10\%;Z),)W,) MECX)%Q&&2KI$],WA$G:7+GD M!54F)6MU2?!\M*1E8S`SC=[G3\:HKT]G?7TP[`W-O;.7\VMM)(TY7Y5Z]EZ+ M'\(9.RH4;#J76?Y;@ZJSH.8%0M$IR!Y:KI`7!F:/L#3!/+=,T[VH>*YYOLG2 M4;3>RKSQH$^N`3O+PIU.9`1E(:/(NY*3A*RM\A&R79$LYB,CIQP=64NE6Y/C MO,BBD)GB,JJQ5(*`=-E(4^!;T`/.YNQJ(54<8=4XXME\\*M=3$1=(7MW^?J- M'[G0"Q=3A01Q'*3;,OQQZJ_I\47T#F)%+QX6OFUXAQ?ARK)&OS.%S:^][T@B M?QW]E;+KZ*SOCBXMCUY.%>T@1J:/P4/X%;]W%"JL!MF"0!S\8HCX/?(3#.^I M\A/7LD,++B[><-Y-4:6DU'Q4@N#@<=X8A)?T#!`V[\!DTV*! #^#5@XKL"[,M2S!=3"/,?@&A,XJB/>O:B(>/=";<29P37> M4Y>/N#Z?`]LWYI=ONM$;*E9NYM8YOIST^'+,J_&*N1T &%Y\._UI;P>02YT(H?U:#"U MQ<.8K[-#V0+.VL=*K_^OI>ZFDHHMG_)DS+>WFO*2A[."35]>6">GB;SA'$QJ M6ZCP`28@-KL]7D\SN[F^UJ;?C,%L^'$\'+![YTRMUS-NQN9P_'%BC(:]H5Y# M[R/XG&9Z)$'E&MI?>GY;Q(0ZLRUP?1"_0%-+)W#AP3FT+<_/*F=2+J]<_N$3 MP<)-WX93RE)B"440D!/H8/HWNFE,]9%FZOV)-C6_[=^79*MLIMO(ZE%/7!X[ MZ?]4_C9FD1*-;;1NU0K?QT)U82/G5L6RQE^EA@83M`092V[(5L#F!/J!>.*: M_M^;81T=04Z=#040644:NI`\W%0N"1!20DWNIR3?9XY\(-XUB)=O.#3(YR2S MHR(&Q0GT!!\-&E3WC'%/GX[W[P,2M373^A,JU!,"Q*LL&/=SQ6I:'8S7;>I? MS:L1[>-*=-C*-3@8%V&W60GD&'<"K:MG7%\/S?!Z UKW7T$_'*FND7XAK4=@WEYHQ;0/DVKZ**)XNRXL MTF`K+L`^]QCBJ3;2V RB_A(7EHGVMT`RU^_0W[<6L10#_Y/U!+`P04 M````"``B8EU`1LRJLJL&``"3,```$0`<`&]R9W,M,C`Q,3$Q,S`N>'-D550) M``.074Y/D%U.3W5X"P`!!"4.```$.0$``.U:VW+;-A!];F?Z#Z@?JB>:9F2G ML6LE0TN4PZDLNA+=)$\9B`1E3"A``<#$^?LN>)$IB:3HR<5.1WD)29Q=[,'! MXJ+U^:N[18P^$2$I9[V.=7C4080%/*1LWNM0R8T7+TY.#:OSZN5OOY[_;AAH M3'@_QB*1R$!T2&."I@E5I/"!NH?'Q]UCA`Q#6\C@EBPP@DZ8/`L)[75NE5J> MF>;=3,2'D@2'<_[)A`;SV9%E&4>6T;4Z.3RB\0K^^?/G0R[FA!%))67!8<`7 MJ8EE=2%DK)2@LT21(1>+`8EP$JM>)V$?$QS3B)(06,5D09A:`Y2:%0;O:HP7 M1"YQ0-IVG$:Z!O[ GIJIJT%=`N9CECN MNFOJYAF69.496FD#GC*I,`O6\*%:ER,'GYA98P%-I#''>+G"1EC.4FS>4"$= MXXPEB^IP0B5,]65)3``9@"*"!AV8*[^<8\:XP@IFD7Z%]^62LHBG+[^<:\9G M!>T)B5`Z7&?:5>]`TL4R)@?YMUM!HMX!=":-0JKW2T$.(;@"(G@,9K7#I9M- M,)$P9=*(1O<=%RZP"+:\;,D)3OB2"$6)7&EV8'X;2B&)'DH)3"BC3Y50C& M)00F)'Z*7`(D'VXF[IJ_VI4N"Y"&XOV`RB#F,A%D M;/LW$\<;>M?.Q/9=;SP]0#3L'>Q$9>'D\=S/R)='\._/(]A7[JWA)7.`O"&Z M=W%N;MJ672:2A!Y[F3YOYG!NF4/JK-;3I)W-AGH51OFG0H'OHXH[[GM7CF^_ M=2KE*# >5"IX)V@E(O>RD:I*A:FFK:F\0X;A9COR[5BG%AC^QQWYF^ M=AR_I,'ZYZ:A?[8Y]+DIRFSW`UZ[$4QOKJ[LR3MO.'4OQ^[0[=MCW^[WO9NQ M[XXOK[V1VW>K]XB6EDVRO=C:/G*G.E]*;M&]7U0XWFM:J^FE!P/5]V#^3\95 MRJVU-VWOUI8^J2G*;?<2-*35Q=3YYP;6?N=?O0%4)]`&IDF*XXI4* [GJ ML\?W^G^_]D8#9Z*GN.N_J\R?;513!AUM9U#)P1]XR>5?*/.SEZ96FL&-XWL3 M9P0GV\&U/:E69AO4E#>G6\*`/?(]E'M`J8N])K6:P(W[RO73BX8]'L#FK`]* MSKCNX-8$;TJ@9ULZE3PA<(76?.T%J[MRPI&YM/(,'#CDNG[%U;,:UY1*)[57 MT/1$O;W>Y4[W6C7=2&']@1%\[?AP&1G5W4\W0$TJ=9MOJVC=U?]'FW.S5*N! ME[5"SCE=++E0**L%CGB0MC34JO2;412L#/W)L)X97>OP3H8=Q"IK=#75+O.A M`=Q7I[+*E.[^5'=O/6_5_:;]UT3`V?AK@RB5V!X<2*D4J`,XJ>NZLG;8IK?4 ML+*::))8R>*+<5]?K`NAL239.I3- ]X(PH M++YLT[:#@"<0,YM#\",RQW%!JJKE25+P!68R(L*>9Q(,*:RJ\R$ALJ#2A'B2 ME-X(Z-V+HC=D)N%I0#Z1F"]U"'TNU8K73MB3).>R@`M805*C-3Y5+=^`0HM% MX1;#L6`[U`M[JG];'0S $:G_=@K'Y?QO`?S.TRS[*YZSD"\P915+&)SQXJGBP8=;'H=$2.=C M`MO(`$Z=`5579#$C8K68M<+^F+2IV4N;+V>[=M.VUH^Z,DRS[U*FLXE^@GO* M=0Q'&=T9G-VNB4@1*TYMX=\RT6#2A]\FT\9$C;B40R[\6W*=.G)82,(N',_@ MJ/JBH+D;]Q/P>T>P*$=]6LFN`O7S<;..VG#3J)^0F]6*F_54N3E11`+E1=T3 M*UWMI\M8.\XHU30^ZJH_(3$L:^$U%K`;K7X!E;N6^YUFCTJJ7`;>Q:0:^V-. M%HK +!57YA;K/TSLH80'=/9?:6#XJ M-7W#61`?W^WF4@EM$?RYF?TP`X__`5!+`0(>`Q0````(`")B74#4FK%P+B4` M`/HD`0`1`!@```````$```"D@0````!O `Q0````(`")B74#FPA0\S`(``$`5 M```5`!@```````$```"D@7DE``!O `L``00E#@``!#D!``!02P$"'@,4````"``B8EU`DN3N1TD+``"X MG@``%0`8```````!````I(&4*```;W)G &UL550% M``.074Y/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`(F)=0,$L@'AS&@`` M?"0!`!4`&````````0```*2!+#0``&]R9W,M,C`Q,3$Q,S!?;&%B+GAM;%54 M!0`#D%U.3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`")B74#QV6TG%0X` M`"W-```5`!@```````$```"D@>Y.``!O `L``00E#@``!#D!``!02P$"'@,4````"``B8EU`1LRJLJL& M``"3,```$0`8```````!````I(%270``;W)G `L``00E#@``!#D!``!02P4&``````8`!@`:`@``2&0````` ` end XML 28 R5.htm IDEA: XBRL DOCUMENT
STATEMENT OF STOCKHOLDERS' DEFICIT (USD $) Common stock Shares Common Stock AmountUSD ($) Additional Paid In CapitalUSD ($) Deficit Accumulated During the Development StageUSD ($) Total Stockholders Equity (Deficit)USD ($)Balance at Apr. 29, 2008 0 Shares issued to founder on June 5, 2008 @ $.0125 per share 56,000,000 1,600 18,400 0 20,000 Private placement @ $0.05 per share 24,500,000 700 34,300 0 35,000 Net loss for the period ended 30/11/2008 $ 0 $ 0 $ (3,500) $ (3,500) Balance at Nov. 30, 2008 80,500,000 2,300 52,700 (3,500) 51,500 Net loss for the year ended 30/11/2009 0 0 (25,648) (25,648) Balance at Nov. 30, 2009 80,500,000 2,300 52,700 (29,148) 25,852 Net loss for the year ended 30/11/2010 0 0 (36,173) (36,173) Balance at Nov. 30, 2010 80,500,000 2,300 52,700 (65,321) (10,321) Effect of 35:1 stock split 5,750 (5,750) 0 0 Net loss for the year ended 30/11/2011 $ 0 $ 0 $ (72,352) $ (72,352) Balance at Nov. 30, 2011 80,500,000 8,050 46,950 (137,673) (82,673) XML 29 R10.htm IDEA: XBRL DOCUMENT
STOCKHOLDERS' EQUITY12 Months Ended Nov. 30, 2011STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY NOTE 4 - STOCKHOLDERS' EQUITYEffective August 31, 2011, the board of directors adopted a resolution toincrease the authorized share capital of the company from 50,000,000 to1,750,000,000 shares of common stock with a par value of $0.0001 per share.Also, effective August 31, 2011, the Company affected a 35 to 1 share split. Asa result the issued and outstanding capital of the Company has been increasedfrom 2,300,000 to 80,500,000 shares of common stock with par value of $0.0001per share.All share and per share data has been adjusted to reflect such stock split.During the period ended November 30, 2008, the Company issued 2,300,000(80,500,000 post-split) common shares for total proceeds of $55,000.As of November 30, 2011, the Company has no warrants or options outstanding.XML 30 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 45 74 1 false 5 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.orgenesisinc.com/20111130/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - BALANCE SHEETS Sheet http://www.orgenesisinc.com/20111130/role/idr_BALANCESHEETS BALANCE SHEETS false false R3.htm 000030 - Statement - BALANCE SHEETS PARENTHETICALS Sheet http://www.orgenesisinc.com/20111130/role/idr_BALANCESHEETSPARENTHETICALS BALANCE SHEETS PARENTHETICALS false false R4.htm 000040 - Statement - STATEMENTS OF OPERATIONS Sheet http://www.orgenesisinc.com/20111130/role/idr_STATEMENTSOFOPERATIONS STATEMENTS OF OPERATIONS false false R5.htm 000050 - Statement - STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://www.orgenesisinc.com/20111130/role/idr_STATEMENTOFSTOCKHOLDERSDEFICIT STATEMENT OF STOCKHOLDERS' DEFICIT false false R6.htm 000060 - Statement - STATEMENTS OF CASH FLOWS Sheet http://www.orgenesisinc.com/20111130/role/idr_STATEMENTSOFCASHFLOWS STATEMENTS OF CASH FLOWS false false R7.htm 000070 - Disclosure - NATURE OF OPERATIONS Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureNATUREOFOPERATIONS NATURE OF OPERATIONS false false R8.htm 000080 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 000090 - Disclosure - DUE TO RELATED PARTY Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureDUETORELATEDPARTY DUE TO RELATED PARTY false false R10.htm 000100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureSTOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY false false R11.htm 000110 - Disclosure - GOING CONCERN Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureGOINGCONCERN GOING CONCERN false false R12.htm 000120 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES false false R13.htm 000130 - Disclosure - INCOME TAXES Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureINCOMETAXES INCOME TAXES false false R14.htm 000140 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.orgenesisinc.com/20111130/role/idr_DisclosureSUBSEQUENTEVENTS SUBSEQUENT EVENTS false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - BALANCE SHEETS Process Flow-Through: 000030 - Statement - BALANCE SHEETS PARENTHETICALS Process Flow-Through: 000040 - Statement - STATEMENTS OF OPERATIONS Process Flow-Through: 000060 - Statement - STATEMENTS OF CASH FLOWS orgs-20111130.xml orgs-20111130.xsd orgs-20111130_cal.xml orgs-20111130_def.xml orgs-20111130_lab.xml orgs-20111130_pre.xml true true